1. Home
  2. ALCO vs MOLN Comparison

ALCO vs MOLN Comparison

Compare ALCO & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alico Inc.

ALCO

Alico Inc.

N/A

Current Price

$37.61

Market Cap

267.7M

Sector

N/A

ML Signal

N/A

Logo Molecular Partners AG

MOLN

Molecular Partners AG

N/A

Current Price

$4.33

Market Cap

157.8M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ALCO
MOLN
Founded
1960
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
267.7M
157.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
ALCO
MOLN
Price
$37.61
$4.33
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$3.75
AVG Volume (30 Days)
29.1K
2.3K
Earning Date
11-24-2025
10-30-2025
Dividend Yield
0.53%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$44,066,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,000.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$24.76
$3.36
52 Week High
$37.90
$5.91

Technical Indicators

Market Signals
Indicator
ALCO
MOLN
Relative Strength Index (RSI) 67.10 53.51
Support Level $36.07 $4.13
Resistance Level $37.90 $4.57
Average True Range (ATR) 0.96 0.14
MACD 0.32 -0.00
Stochastic Oscillator 95.33 54.03

Price Performance

Historical Comparison
ALCO
MOLN

About ALCO Alico Inc.

Alico Inc is a Florida-based agribusiness and land management company that primarily focuses on citrus production and grove conservation. The company operates through two primary business units: Alico Citrus and Land Management and Other Operations. The Alico Citrus segment engages in the cultivation of citrus trees and delivers citrus to the processed and fresh citrus markets. It mainly serves the processed market and sells primarily Hamlin oranges and the Valencia variety to the orange juice processors. The Land Management and Other Operations segment engages in land leasing for recreational, conservation, and mining activities. Alico Citrus delivers most of the revenue as the firm's primary operating business unit.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: